Linked Life Data

14695833

Source:http://linkedlifedata.com/resource/pubmed/id/14695833

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14695833rdf:typepubmed:Citationlld:pubmed
pubmed-article:14695833lifeskim:mentionsumls-concept:C0011860lld:lifeskim
pubmed-article:14695833lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:14695833lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:14695833lifeskim:mentionsumls-concept:C0166417lld:lifeskim
pubmed-article:14695833lifeskim:mentionsumls-concept:C0002482lld:lifeskim
pubmed-article:14695833lifeskim:mentionsumls-concept:C0268563lld:lifeskim
pubmed-article:14695833lifeskim:mentionsumls-concept:C1517589lld:lifeskim
pubmed-article:14695833lifeskim:mentionsumls-concept:C1956427lld:lifeskim
pubmed-article:14695833pubmed:issue1lld:pubmed
pubmed-article:14695833pubmed:dateCreated2003-12-29lld:pubmed
pubmed-article:14695833pubmed:abstractTextA series of benzoxazinones has been synthesized and tested for PPARgamma agonist activity. Synthetic approaches were developed to provide either racemic or chiral compounds. In vitro functional potency could be measured through induction of the aP2 gene, a target of PPARgamma. These studies revealed that compounds with large aliphatic chains at the nitrogen of the benzoxazinone were the most potent. Substitution of the chain was tolerated and in many cases enhanced the in vitro potency of the compound. Select compounds were further tested for metabolic stability, oral bioavailability in rats, and efficacy in db/db mice after 11 days of dosing. In vivo analysis with 13 and 57 demonstrated that the series has potential for the treatment of type 2 diabetes.lld:pubmed
pubmed-article:14695833pubmed:languageenglld:pubmed
pubmed-article:14695833pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695833pubmed:citationSubsetIMlld:pubmed
pubmed-article:14695833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695833pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695833pubmed:statusMEDLINElld:pubmed
pubmed-article:14695833pubmed:monthJanlld:pubmed
pubmed-article:14695833pubmed:issn0022-2623lld:pubmed
pubmed-article:14695833pubmed:authorpubmed-author:BurrisThomas...lld:pubmed
pubmed-article:14695833pubmed:authorpubmed-author:DudashJosephJ...lld:pubmed
pubmed-article:14695833pubmed:authorpubmed-author:ChenXiaoliXlld:pubmed
pubmed-article:14695833pubmed:authorpubmed-author:DemarestKeith...lld:pubmed
pubmed-article:14695833pubmed:authorpubmed-author:RybczynskiPhi...lld:pubmed
pubmed-article:14695833pubmed:authorpubmed-author:ZeckRoxanne...lld:pubmed
pubmed-article:14695833pubmed:authorpubmed-author:CombsDonald...lld:pubmed
pubmed-article:14695833pubmed:authorpubmed-author:YangMariaMlld:pubmed
pubmed-article:14695833pubmed:authorpubmed-author:OsborneMelvil...lld:pubmed
pubmed-article:14695833pubmed:issnTypePrintlld:pubmed
pubmed-article:14695833pubmed:day1lld:pubmed
pubmed-article:14695833pubmed:volume47lld:pubmed
pubmed-article:14695833pubmed:ownerNLMlld:pubmed
pubmed-article:14695833pubmed:authorsCompleteYlld:pubmed
pubmed-article:14695833pubmed:pagination196-209lld:pubmed
pubmed-article:14695833pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:meshHeadingpubmed-meshheading:14695833...lld:pubmed
pubmed-article:14695833pubmed:year2004lld:pubmed
pubmed-article:14695833pubmed:articleTitleBenzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model.lld:pubmed
pubmed-article:14695833pubmed:affiliationJohnson and Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, New Jersey 08869, USA. prybczyn@prdus.jnj.comlld:pubmed
pubmed-article:14695833pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14695833pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:14695833lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14695833lld:pubmed